Nurse Practitioner, Adult Health · New York, NY
NPI
1881148930
Since 2016
Specialty
Nurse Practitioner, Adult Health
Code 363LA2200X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
1275 York Ave
New York, NY, 10065
Phone (212) 639-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$23K
324 services
Medicare patients, 2024
171
Average age 74
Drug cost, 2024
$6.6M
697 prescriptions
Company payments, 2024
$648
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marisa J Hine was code 99214 (office e&m - established), 184 times for 107 patients. In total Marisa J Hine billed 324 services in 5 codes, and Medicare paid $23K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-08-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 184 | 107 | $75.42 | $14K |
| 99213 Office E&M - Established | Office | 104 | 60 | $54.66 | $5,685 |
| 99215 Office E&M - Established | Office | 24 | 19 | $104.09 | $2,498 |
By year: 2022 $20K for 319 services; 2023 $10K for 165 services; 2024 $23K for 324 services.
Medicare prescription drug claims, 2024
In 2024, the drug Marisa J Hine prescribed most often to Medicare patients was Scemblix (Asciminib Hydrochloride), with 74 prescriptions and refills. In total Marisa J Hine wrote 697 Medicare prescriptions that cost $6.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Scemblix Asciminib Hydrochloride | 74 | 84 | 11 | $1.5M |
| Imatinib Mesylate Generic | 72 | 104 | 11 | $335K |
| Sprycel Dasatinib | 58 | 58 | 11 | $620K |
| Hydroxyurea Generic | 56 | 126 | 24 | $1,515 |
| Jakafi Ruxolitinib Phosphate | 54 | 54 | Under 11 | $907K |
| Calquence Acalabrutinib Maleate | 41 | 41 | Under 11 | $600K |
| Acyclovir Generic | 38 | 54 | 15 | $544 |
| Allopurinol Generic | 26 | 44 | Under 11 | $224 |
| Valacyclovir Valacyclovir Hcl | 25 | 33 | Under 11 | $954 |
| Levofloxacin Generic | 23 | 29 | 13 | $620 |
| Ojjaara Momelotinib Dihydrochloride | 23 | 23 | Under 11 | $731K |
| Venclexta Venetoclax | 20 | 20 | Under 11 | $205K |
| Ondansetron Odt Ondansetron | 20 | 20 | Under 11 | $316 |
| Gleevec Imatinib Mesylate | 18 | 45 | Under 11 | $358K |
| Brukinsa Zanubrutinib | 18 | 18 | Under 11 | $265K |
Brand drugs: 365 claims; generic drugs: 332 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Marisa J Hine $648 ($648 in general payments such as food, travel and fees) from 1 company. The largest payer was Novartis Pharmaceuticals Corporation with $648.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 1 | $648 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.